FundraiseNov 13, 2026, 05:24 UTC

vVARDIS prices discounted NYSE IPO, raising $175M

What's the deal? vVARDIS, a Zug-based dental med-tech company, priced its initial public offering at $18 per share, raising about $175 million. It sold 9.72 million Class A shares and will begin trading on the New York Stock Exchange on November 13, 2026 under the ticker "VVVV."

Why now? vVARDIS reached unicorn status earlier this year and used the IPO filing to update investors on its business. For the first half of 2026, it reported revenue of $28.6 million — more than triple a year earlier — against a net loss of $27.8 million.

What's the endgame? The company sells Curodont, a peptide-based treatment for early-stage cavities applied in a dental office in five minutes or less, with no drilling or needles. Its mission, it says, is "a world where cavity treatment is drill-free, regenerative and accessible to all."

What could go wrong? vVARDIS priced below its marketed $21–$24 range and cut its share sale by more than 12%, a sign of softer demand. Reuters tied the downsizing to a tech-led selloff and rising market uncertainty.

Its US business also leans heavily on one customer: distributor Henry Schein accounted for 90% of sales in the first half of 2026, up from 62% a year earlier, with no minimum purchases set.

By the numbers: At its midpoint target, vVARDIS had sought a fully diluted value of about $1.4 billion. Goldman Sachs and J.P. Morgan led the offering, with William Blair, UBS Investment Bank, and Deutsche Bank as bookrunners.

The signal: The discounted debut is a qualified entry rather than proof of strong IPO appetite. The same unsettled backdrop is testing demand for other large offerings, including the closely watched Anthropic deal.